Staging and Restaging Pediatric Abdominal and Pelvic Tumors

Targeted CE per ARRT’s Discipline, Category, and Subcategory classification for enrollments starting after February 10, 2026:
[Note: Discipline-specific Targeted CE credits may be less than the total Category A credits approved for this course.]

Computed Tomography: 1.50
Procedures: 1.50
Abdomen and Pelvis: 1.50

Magnetic Resonance Imaging: 1.50
Procedures: 1.50
Body: 1.50

Nuclear Medicine Technology: 1.50
Procedures: 1.50
Endocrine and Oncology Procedures: 1.50

Radiography: 1.00
Procedures: 1.00
Thorax and Abdomen Procedures: 1.00

Registered Radiologist Assistant: 1.50
Procedures: 1.50
Abdominal Section: 1.50

Sonography: 1.00
Procedures: 1.00
Abdomen: 1.00

Radiation Therapy: 3.00
Procedures: 3.00
Treatment Sites and Tumors: 3.00

Outline

1. Introduction
2. Neuroblastoma
   1. Diagnostic Pearls and Pitfalls
   2. Neuroblastoma Staging
   3. Neuroblastoma Treatment Response Assessment
3. Wilms Tumor
   1. Diagnostic Pearls and Pitfalls
   2. Wilms Tumor Staging
   3. Wilms Tumor Treatment Response Assessment
4. Hepatoblastoma
   1. Diagnostic Pearls and Pitfalls
   2. Hepatoblastoma Staging
   3. Hepatoblastoma Treatment Response Assessment
5. Lymphomas
   1. Hodgkin Lymphoma: Diagnostic Pearls and Staging
   2. Non-Hodgkin Lymphoma: Diagnostic Pearls and Staging
   3. Lymphoma Treatment Response Assessment
6. Abdominal and Pelvic GCTs
   1. Diagnostic Pearls and Pitfalls
   2. Abdominal and Pelvic GCT Staging
   3. Abdominal and Pelvic GCT Treatment Response Assessment
7. Abdominal and Pelvic Rhabdomyosarcomas
   1. Diagnostic Pearls and Pitfalls
   2. Rhabdomyosarcoma Staging
   3. Rhabdomyosarcoma Response Assessment
8. Conclusion

Objectives

Upon completion of this course, students will:

1. identify the most common benign abdominal mass found in children
2. be familiar with the percentage of neuroblastoma cases diagnosed before the age of 5
3. be familiar with the imaging techniques effective in staging and restaging neuroblastomas
4. be familiar with the sensitivity and specificity of MIBG imaging for neuroblastomas
5. recognize the percentage of neuroblastomas that are MIBG negative at diagnosis
6. identify the modality with promise for potential staging and monitoring neuroblastomas
7. be familiar with INSS staging
8. be familiar with the INRGSS staging system
9. be familiar with what is recognized as stage M in the classification system
10. identify the most common site of distant metastases in neuroblastomas
11. be familiar with the classification for metastatic disease isolated to skin, liver, and/or bone marrow in children younger than 18 months
12. be familiar with us of ADC values as they relate to outcomes for neuroblastoma patients
13. be familiar with SIOPEN scoring at follow-up for evaluating response in neuroblastoma
14. be familiar with the measurement lymph nodes in neuroblastoma
15. identify the most common renal malignancy in children
16. be familiar with the common clinical presentations of Wilms tumor
17. identify the key feature that helps distinguish Wilms tumor from neuroblastoma
18. recognize the imaging modalities that can be used to calculate tumor volume in Wilms tumor
19. identify the common location for a hepatoblastoma at the time of presentation
20. be familiar with the common characteristics of hepatoblastoma on US
21. be familiar with the considerations before initiating chemotherapy in pediatric patients with suspected primary liver tumor
22. identify the imaging modality recommended for abdominal evaluation in pediatric patient with suspected liver neoplasms
23. be familiar with the staging system recommended for pediatric patients with hepatoblastomas
24. identify the preferred imaging modality for evaluation hepatoblastomas during neoadjuvant chemotherapy
25. identify the staging system currently used for Hodgkin lymphoma
26. be familiar with the appropriate classification for Hodgkin lymphoma involving solid abdominal organs
27. understand why FDG PET is an important tool in assessing lymphoma
28. be familiar with the cells GCTs are derived from
29. be familiar with the hallmarks of teratomas in nonseminomatous GCTs
30. be familiar with the use of MRI when scrotal US are inconclusive or inconsistent in GCT pediatric patients
31. be familiar with the common site of solid organ metastases after the lungs in GCTs
32. recognize the limitations of staging pediatric GCTs
33. identify the most common location for rhabdomyosarcomas in pediatric patients
34. know the three key pieces of information that are necessary to divide patients into risk groups for rhabdomyosarcoma staging
35. identify the preferred imaging modality for evaluation pediatric soft tissue sarcomas like rhabdomyosarcoma
36. know the accepted ways to assess rhabdomyosarcoma treatment response
37. be familiar with the criteria outlined in RECIST 1.1 for rhabdomyosarcoma